Antagonistic activity of tamsulosin against human vascular α1- adrenergic receptors

Clinical Pharmacology and Therapeutics

Volumn 67, Issue 4, 2000, Pages 405-412

  Harada, Kazuhiro ^a   Kawaguchi, Atsuhiro ^b   Ohmori, Masami ^b   Fujimura, Akio ^b  

^a JICHI MEDICAL UNIVERSITY   (Japan)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 1 ADRENERGIC RECEPTOR; TAMSULOSIN;

ADULT; ARTICLE; BLOOD VESSEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIASTOLIC BLOOD PRESSURE; DOSE RESPONSE; DRUG ANTAGONISM; DRUG BLOOD LEVEL; HUMAN; MALE; NORMAL HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECEPTOR BLOCKING; SYSTOLIC BLOOD PRESSURE; VASOCONSTRICTION;

EID: 0034061609     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1067/mcp.2000.105354     Document Type: Article

References (37)

1. 1. Hedlund H, Andersson KE, Larsson B. α-Adrenoceptors and muscarinic receptors in the isolated human prostate. J Urol 1985;134:1921-8.
2. 2. Kunisawa Y, Kawabe K, Nijima T, Honda K, Takenaka T. A pharmacological study of α-adrenergic receptor subtypes in smooth muscles of human urinary bladder base and prostatic urethra. J Urol 1985;134:396-8.
3. 3. Mets TF. Drug-induced orthostatic hypotension in older patients. Drugs Aging 1995;6:219-28.
4. 4. Kawabe K, Ueno A, Takimoto Y, Aso Y, Kato H, Kitagawa R, et al. [Clinical evaluation of YM617 on bladder outlet obstruction associated with benign prostatic hypertrophy: a double-blind, multi-center study compared with placebo] [in Japanese]. Jpn J Urol Surg 1991;4:231-42.
5. 5. Michel MC, Bressel HU, Mehlburger L, Goepel M. Tamsulosin: real life clinical experience in 19,365 patients. Eur Urol 1998;34(suppl 2):37-45.
6. 1A-adrenoceptor antagonists in benign prostatic hyperplasia: studies on tamsulosin in a fixed dose and terazosin in increasing doses. Br J Urol 1997;80:606-11.
7. 1-adrenoceptor antagonist binding in human prostate and aorta. Clin Exp Pharmacol Physiol 1994;21:405-11.
8. 1-Adrenoceptor subtype selectivity of tamsulosin: studies using livers from different species. Eur J Pharmacol 1995;289:1-7.
9. 1-adrenoceptors to characterize subtype selectivity of drugs for the treatment of prostatic hypertrophy. Eur J Pharmacol 1995;288:201-7.
10. 1-adrenergic receptor subtypes. Prostate 1997;33:55-9.
11. 1-adrenergic receptor subtypes in human prostate. J Urol 1993; 150:546-54.
12. 1-Adrenoceptor subtype affinities of drugs for the treatment of prostatic hypertrophy. Naunyn Schmiedebergs Arch Pharmacol 1993;348:385-95.
13. 1-adrenoceptor subtypes and in human prostate. J Auton Pharmacol 1996; 16:21-8.
14. 1-Adrenoceptors in the human prostatic urethra are different from those of the human peripheral arteries. Clin Investig 1993;72:55.
15. 1-adrenoceptor subtypes mediating the contraction of human prostatic urethra and peripheral artery. Br J Pharmacol 1994;113:723-8.
16. 1-adrenoceptors. Jpn J Pharmacol 1999;80:209-15.
17. 1-adrenoceptors in human. Naunyn Schmiedebergs Arch Pharmacol 1996;354:557-61.
18. 1-adrenoceptor blocker tamsulosin in human liver microsomes. Xenobiotica 1998;10:909-22.
19. 19. Aellig WH. Clinical pharmacology, physiology and pathophysiology of superficial veins - I. Br J Clin Pharmacol 1994;38:181-96.
20. 20. Holloway GA Jr, Watkins DW. Laser Doppler measurement of cutaneous blood flow. J Invest Dermatol 1977; 69:306-9.
21. 1-adrenoceptor antagonists, prazosin and urapidil, on a finger skin vasoconstrictor response to cold stimulation. Eur J Clin Pharmacol 1996;49:371-6.
22. 22. Khan F, Struthers AD, Spence VA. The effect of prazosin on skin microcirculation as assessed by laser Doppler flowmetry. Br J Clin Pharmacol 1988;26:267-72.
23. 1-adrenoceptor antagonist: second report - a single oral dose of controlled release formulation in healthy male subjects] [in Japanese]. J Clin Ther Med 1990;6:2529-51.
24. 24. Soeishi Y, Kobori M, Kobayashi S, Higuchi S. Sensitive method for the determination of amsulosin in human plasma using high-performance liquid chromatography with fluorescence detection. J Chromatogr 1990;533:291-6.
25. 25. Beduschi R, Beduschi MC, Oesterling JE. Benign prostatic hyperplasia: use of drug therapy in primary care. Geriatrics 1998;53:33-9.
26. 1-adrenoceptor antagonist: a meta-analysis of two randomized, placebo-controlled multicentre studies in patients with benign prostatic obstruction (symptomatic BPH). European Tamsulosin Study Group. Eur Urol 1996;29:155-67.
27. 27. Lindblad LE, Ekenvall L. Alpha-adrenoceptors in the vessels of human finger skin. Acta Physiol Scand 1986;128: 219-22.
28. 28. Schutzman J, Jaeger F, Maloney J, Fouad-Tarazi F. Head-up tilt and hemodynamic changes during orthostatic hypotension in patients with supine hypertension. J Am Coll Cardiol 1994;24:454-61.
29. 29. Applegate WB, Davis BR, Black RH, Smith WM, Miller ST, Burlando AJ. Prevalence of postural hypotension at baseline in the Systolic Hypertension in the Elderly Program (SHEP) Cohort. J Am Geriatr Soc 1991;39: 1057-65.
30. 30. Vanhoutte PM. Aging and vascular responsiveness. J Cardiovasc Pharmacol 1988;12(suppl 8):S11-8.
31. 1-adrenoceptor antagonist: third report - multiple oral doses of controlled release formulation in healthy male subjects] [in Japanese]. J Clin Ther Med 1991;7:63-83.
32. 32. Wolzt M, Fabrizii V, Dorner GT, Zanaschka G, Leufkens P, Krauwinkel WJJ, et al. Pharmacokinetics of tamsulosin in subjects with normal and varying degrees of impaired renal function: an open-label single-dose and multiple-dose study. Eur J Clin Pharmacol 1998;54:367-73.
33. 33. Chappel CR, Baert L, Thind P, Hofner K, Khoe GS, Spangberg A. Tamsulosin 0.4 mg once daily: tolerability in older and younger patients with lower urinary tract symptoms suggestive of benign prostatic obstruction (symptomatic BPH). The European Tamsulosin Study Group. Eur Urol 1997;32:462-70.
34. 34. Narayan P, Tewari A. A second phase III multicenter placebo controlled study of 2 dosages of modified release tamsulosin in patients with symptoms of benign prostatic hyperplasia. United States 93-01 Study Group. J Urol 1998;160:1707-8.
35. 1-adrenoceptor antagonist for the treatment of symptomatic benign prostatic hyperplasia. Drugs Today 1996;32:259-68.
36. 36. Docci D, Bilancioni R, Pistocchi E, Mosconi G, Truci F, Salvi G, et al. Serum alpha-1-acid glycoprotein in chronic renal failure. Nephron 1985;39:160-3.
37. 37. Morita M, Numahata K, Ogawa Y, Suzuki K. [The concentration of tamsulosin hydrochloride in the blood and prostatic tissue of the patients in benign prostatic hyperplasia] [in Japanese]. Nippon Hinyokika Gakkai Zasshi 1997;88:535-40.